| Target Professions: | DO, MD, Nurse, Nurse Practitioner, Physician Assistant, Dietitian, Pharmacist |
| Target Specialties: | Nephrology, Nutrition, Pharmacy |
| Credits Available: | 4.5 AMA PRA Category 1 Credit™, Maintenance of Certification (MOC) points available |
Chronic kidney disease (CKD) is estimated to impact approximately 37 million individuals in the United States (U.S). Furthermore, about 786,000 persons are living with end-stage kidney disease (ESKD) and receive renal replacement therapy, either through maintenance dialysis or kidney transplantation. Hyperphosphatemia, characterized by phosphorus levels in the bloodstream exceeding the normal parameters of 2.5–4.5 mg/dL, constitutes a critical aspect of the mineral and bone disorder associated with CKD. Elevated levels of serum phosphorus facilitate vascular calcification, impair endothelial function, and may play a role in other newly identified mechanisms of cardiovascular toxicity specific to CKD. The treatment of hyperphosphatemia in patients with CKD requiring dialysis is complex and is ideally managed by a multidisciplinary team of care providers including nephrologists, advanced practice providers (APPs), nurses, dietitians, pharmacists, and other healthcare professionals. Evidence suggests that multidisciplinary care models can slow the progression of CKD and improve mortality rates, but gaps remain in the availability and implementation of these models across different healthcare settings. These challenges include dietary management, optimization of dialysis, pharmacological interventions, patient education, addressing adherence concerns, and the need for comprehensive care models. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with hyperphosphatemia.
The following questions are intended to assess your knowledge and practice of key aspects in the management of hyperphosphatemia in CKD patients requiring dialysis..
This module will begin with an overview of hyperphosphatemia in CKD, specifically in patients on dialysis, including its prevalence and impact on patient outcomes.
This module will begin with the impact of hyperphosphatemia in chronic kidney disease (CKD). Then we will cover the MoA of phosphate binders broadly. Then we will cover the MoA of tenapanor specifically, contrasting it with phosphate binders.
This module will begin with evidence for the recently approved tenapanor for hyperphosphatemia. This will encompass three trials leading to its approval. Then, we will cover evidence for more recently approved phosphate binders individually.
The following questions are intended to assess your gained knowledge and practice of key aspects in the management of hyperphosphatemia in CKD patients requiring dialysis..
During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with hyperphosphatemia in patients with CKD on dialysis.
65 yo female on hemodialysis with continued hyperphosphatemia despite treatment with phosphate binders. Considerations for current therapy re-assessment and considerations for add-on therapy.
72 yo male on hemodialysis with hyperphosphatemia on treatment with phosphate binders with possible sequelae of hyperphosphatemia.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management of hyperphosphatemia in your patients with CKD on dialysis.
During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.
